Actively Recruiting
AvertD Post-Approval Study
Led by Prescient Medicine Holdings, Inc. · Updated on 2025-08-22
4000
Participants Needed
1
Research Sites
363 weeks
Total Duration
On this page
Sponsors
P
Prescient Medicine Holdings, Inc.
Lead Sponsor
C
Caron Treatment Centers
Collaborating Sponsor
AI-Summary
What this Trial Is About
A Prospective Post-Approval Study of AvertD to Evaluate Device Performance, Prescribing Impact, and Labeling Comprehension in the Intended Use Population
CONDITIONS
Official Title
AvertD Post-Approval Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Prior to first opioid prescription
- Being considered for first oral opioid prescription lasting 4 to 30 days
- Prescribed AvertD as part of care
- Willing and able to complete yearly assessments for 5 years
- Signed informed consent
You will not qualify if you...
- Planned opioid prescription less than 4 days or more than 30 days
- Any condition making participation unsafe or infeasible according to investigator judgment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Concentrics Research
Indianapolis, Indiana, United States, 46240
Actively Recruiting
Research Team
A
Amanda Smith, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here